Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
about
FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATIONConcordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastasesColorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?Can we accurately report PTEN status in advanced colorectal cancer?Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patientsMutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue.Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients.Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.Functions and Regulation of the PTEN Gene in Colorectal Cancer.Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.Management of resectable colorectal lung metastases.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Molecular pathology in real time.Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pieTumor heterogeneity and personalized cancer medicine: are we being outnumbered?Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation.KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers.Ex Vivo and In Vivo Noninvasive Imaging of Epidermal Growth Factor Receptor Inhibition on Colon Tumorigenesis Using Activatable Near-Infrared Fluorescent Probes.Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case reportMolecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatmentCombined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently.Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?Molecular Biomarkers for the Evaluation of Colorectal Cancer.Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles.Mutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers
P2860
Q28066171-0DA79670-B41A-4B83-8966-D0C2947D1BF8Q28088489-E1EC4657-F182-4003-881D-353511252C5BQ34207776-664DAA1E-700D-4281-A39F-2825AFB17651Q35101357-A3F369C7-9B61-46FC-A345-D1724C43757FQ35223898-F8A0F577-2DC2-430A-BCEC-DC13B4A6DB4AQ35527809-EFA21BDC-250B-47D5-8A42-51A624CDA5B8Q35986751-7C08FBFE-D390-4A89-B163-F75188B5A646Q36977406-DB9C10BF-6761-4715-8566-0F9AE98F4A50Q37121274-AB5E0702-79AD-490C-80FD-5901A07E804EQ37236257-1AB22283-2795-447C-9753-DB166E6EAC91Q37269424-ECFBEAD2-A24B-4D68-8302-218ADB07C728Q37373790-3341EA2F-AA88-4FD1-8BEB-4E0E79BF48C6Q38182985-5EAEEB16-8D40-47F3-9CAC-4A6E5F404ECEQ38265382-B1F8B4D1-EA0B-4A3A-8DA4-8AAD7286483AQ38481038-C0E01210-E38D-4ADE-A4ED-5E7E7F8E4B10Q38545768-0F5D2512-B150-4D01-9E4D-0AD0CE99BFCAQ38667176-040F8D6B-0652-4924-8F07-6B3EB6110B7DQ38697494-B6F8F832-053A-493E-A4DA-D437418DCF35Q38756841-6832810F-19A3-49FC-9EBF-BFFE33DC8022Q39172118-F9144A1F-AB75-4288-938F-E8E12775B055Q39246718-180E372B-B0E5-41CA-9C03-93B7172D0BE5Q39796293-98C406A6-D380-4CDC-8A2A-6DEC363C897AQ40341349-9A97DEA1-0AF7-4C38-9803-46D1A1344B6AQ40825640-BBE8F378-B7BF-4BD7-8B54-2A75A289C786Q40881896-76067EEF-0464-4F25-AEF9-9EB47AB84159Q41232207-C8587769-21FA-403B-A290-B50C45048158Q41621539-349B2816-106D-4F0F-8E29-EF10B406D998Q42371494-5A76F89F-ED28-49F5-92DD-C7FA66B86A85Q43805357-8C14DE1D-A658-409C-B4DA-A3420425A8F1Q45353745-055D05E3-83C9-4C90-B1F9-203071983E6AQ45376093-8229BF8C-D767-4229-87D5-DACD681460C1Q45711137-B55C2AB0-F3CF-4562-B3FE-FD5305D6B06AQ48197461-6944E49A-6071-41A0-85F8-0024199CB066Q49197514-71A11520-7B63-44D5-B439-4DD85D8D984CQ51836491-9D43B6EA-0177-4F2B-9F5C-A927C506DD8FQ52794464-4BAE9BB6-E0C8-4D52-938D-F9D4B3CB14FAQ55003977-F4136A0D-D48F-478D-A431-BCF40B0D448FQ58707595-04103E8D-B18D-4811-B10E-F9C7731166C1
P2860
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Concordance of predictive mark ...... n colorectal cancer: a review.
@en
Concordance of predictive mark ...... n colorectal cancer: a review.
@nl
type
label
Concordance of predictive mark ...... n colorectal cancer: a review.
@en
Concordance of predictive mark ...... n colorectal cancer: a review.
@nl
prefLabel
Concordance of predictive mark ...... n colorectal cancer: a review.
@en
Concordance of predictive mark ...... n colorectal cancer: a review.
@nl
P2093
P2860
P1433
P1476
Concordance of predictive mark ...... n colorectal cancer: a review.
@en
P2093
Hans Gelderblom
Hans Morreau
Jara M Baas
Lisanne L Krens
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0024
P577
2011-07-08T00:00:00Z